TLX

Telix Pharmaceuticals Ltd

Add to Watchlist

Advanced Chart

17.570

-1.230(-6.540%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

17.900

Open

17.210

VWAP

17.43

Vol

72.51K

Mkt Cap

5.94B

Low

17.000

Amount

1.26M

EV/EBITDA(TTM)

181.65

Total Shares

675.76M

17.98B

EV/OCF(TTM)

417.89

P/S(TTM)

11.76

Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.

Valuation Metrics

The current forward P/E ratio for Telix Pharmaceuticals Ltd (TLX.O) is 63.01, compared to its 5-year average forward P/E of 78.87. For a more detailed relative valuation and DCF analysis to assess Telix Pharmaceuticals Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

78.87

Current PE

63.01

Overvalued PE

92.71

Undervalued PE

65.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

49.30

Current EV/EBITDA

44.83

Overvalued EV/EBITDA

58.53

Undervalued EV/EBITDA

40.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

7.70

Current PS

7.07

Overvalued PS

8.99

Undervalued PS

6.42